CN110448621A - A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis - Google Patents
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis Download PDFInfo
- Publication number
- CN110448621A CN110448621A CN201910834238.7A CN201910834238A CN110448621A CN 110448621 A CN110448621 A CN 110448621A CN 201910834238 A CN201910834238 A CN 201910834238A CN 110448621 A CN110448621 A CN 110448621A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- necrotizing enterocolitis
- ginkgo
- treating chicken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis, which is calculated as: 10-50 parts of galla turcica, 5-45 parts of ginkgo, 1-30 parts of pueraria lobata, 1-20 parts of lotus leaf, 1-15 parts of green tea.And specifically disclose the preparation method of the medicament composition granule agent.The use of Chinese medicine composition of the invention to antibiotic during reduction fowl raising, improves the health status of chicken, and the food safety for improving chicken and its product is of great significance, and economic benefit and social prospect are considerable.
Description
Technical field
The invention belongs to field of veterinary medicine preparation, and in particular to a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis.
Background technique
Chicken necrotizing enterocolitis (Necrotic enteritis, NE) is a kind of intestines problem of pathogenesis complexity, mainly
Chicken small intestinal mucosa necrosis is caused to be a kind of acute bacterial disease of main feature by C.perfringens secretion exotoxin.Except this
Except further include a series of risk factor.Usually secondary to globidiosis, the rate of body weight gain of broiler chicken is caused to decline, the death rate rises,
Economic loss directly or indirectly is caused to poultry production.
Prevention is focused at present, in addition to keeping dry, ventilation of henhouse etc., can generally be vaccinated such as C.perfringens epidemic disease
Seedling, inactivated vaccine, toxoid vaccine and recombinant protein vaccine etc.；But treatment aspect mostly uses greatly antibiotic and antibacterial agent such as mould
Element, tylosin, sharp proceomycin etc., but the problems such as antibiotic resistance and food antibiotics of animal residual, takes place frequently, antibiotic
Human body may be entered with food chain, be detrimental to health.Therefore Chinese medicine composition of the invention essentially consists in reduction fowl raising
The use of antibiotic in the process improves the health status of chicken.
Summary of the invention
The present invention is intended to provide a kind of pharmaceutical composition of the treatment chicken necrotizing enterocolitis of energy substitute antibiotics.
For achieving the above object, the present invention treats the pharmaceutical composition of chicken necrotizing enterocolitis, specific embodiment are as follows:
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the pharmaceutical composition main component parts by weight meter
Are as follows: 10-50 parts of galla turcica, 5-45 parts of ginkgo, 1-30 parts of pueraria lobata, 1-20 parts of lotus leaf, 1-15 parts of green tea.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the pharmaceutical composition main component parts by weight
Number is calculated as: 22-45 parts of galla turcica, 15-35 parts of ginkgo, 15-25 parts of pueraria lobata, 5-18 parts of lotus leaf, 1-10 parts of green tea.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the pharmaceutical composition main component parts by weight
Number is calculated as: 27-30 parts of galla turcica, 15-22 parts of ginkgo, 15-18 parts of pueraria lobata, 10-15 parts of lotus leaf, 7-10 parts of green tea.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the pharmaceutical composition main component parts by weight
Number is calculated as: 30 parts of galla turcica, 15 parts of ginkgo, 18 parts of pueraria lobata, 10 parts of lotus leaf, 7 parts of green tea.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the drug combination preparation be granule,
Capsule, tablet, pill.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the drug combination preparation are granule.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the drug combination preparation granule preparation
Technique are as follows:
(1) galla turcica, ginkgo, pueraria lobata are crushed, it is standby；
(2) extraction process by water: smashed galla turcica, ginkgo, pueraria lobata, lotus leaf, green tea are impregnated for 24 hours in 37 DEG C of warm water, reflux
It extracts, adds 5-15 times of water multiple, return time 2-5h, extraction time 1-3 times, filter, be concentrated into medical fluid ratio 1:1-1:10, it is standby
With；
(3) process for refining: being added 40 ~ 80% ethyl alcohol in (2), and 24 ~ 48h is stood after stirring, and filtering is recycled ethyl alcohol, is concentrated into thick
Cream, density 1.10, temperature is 40-60 DEG C, dry, obtains medicinal extract, crushing sieves with 100 mesh sieve, spare；
(4) proper auxiliary materials will be added in above-mentioned medicinal extract and granule is made.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of the present invention, the drug combination preparation granule preparation
Auxiliary material described in technique is lactose, microcrystalline cellulose, one or more combinations in mannitol.
A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of preparation of the present invention is in treatment chicken necrotizing enterocolitis
Application.
Main component Toxicity Analysis of the present invention:
Galla turcica: bitter, it is warm-natured.Enter lung, spleen, kidney channel.Puckery intestines, controlling nocturnal emission with astringent drugs, cough-relieving, hemostasis, sore.Protracted dysentery and diarrhea is passed out semen, and is stolen
Sweat is coughed, hemoptysis, hematochezia, hemorrhoid blood, wound hemorrhage, and sore does not close up long, aphtha, dentalgia.
Ginkgo: mild-natured, bitterness sweet in flavor, it is slightly poisonous；Enter lung, kidney channel.Warming lung, benefiting vital energy, relieving asthma and cough reduce just, only gonorrhoea；It is raw
The disinfection of food drop phlegm, desinsection.
Pueraria lobata: it is sweet in flavor, pungent, it is cool in nature.It attaches to the lung and stomach meridians.Expelling pathogenic factors from muscles and skin is brought down a fever, and promoting eruption promotes the production of body fluid to quench thirst, Shengyang Zhixie.For exterior syndrome
Fever, stiff nape and back, measles without adequate eruption, pyreticosis is thirsty, and the deficiency of Yin is quenched one's thirst, and heat is purged heat dysentery, splenasthenic diarrhea.
Lotus leaf: bitterly micro-puckery, nature and flavor cool in nature are cold and cool, return heart, liver, the spleen channel.Cure mainly hot summer weather polydipsia, headache and dizziness, oedema,
Deficiency of food abdominal distension, dysentery, leukorrhea, rectal prolapse are spitted blood, bleeding from five sense organs or subcutaneous tissue, hemoptysis, hematochezia, metrorrhagia and metrostaxis, post partum longtime lochia, traumatic blood stasis.
Green tea: refresh oneself clear away heart-fire, the weight-reducing of clearing away heat, relieving summer heat, promoting digestion and resolving phlegm, eliminating greasiness, relieving restlessness and restlessness, removing toxic substances sober up, promote the production of body fluid to quench thirst, fall fire
Improving eyesight, stop dysentery dehumidifying.
The present invention by research discovery galla turcica and ginkgo formula rate to the sensibility of C.perfringens pathogenic bacteria and
Bacteriostasis, maximum to C.perfringens antibacterial circle diameter when galla turcica and ginkgo mass ratio 1:1, strongest bacteriostatic effect.Its
Secondary galla turcica and ginkgo mass ratio 1.5:1, galla turcica and ginkgo mass ratio 2:1.
The present invention is include at least the following beneficial effects:
The first, Chinese medicine composition of the invention is instructed according to traditional Chinese medicine theory, and each component Chinese medicine is carried out scientific compatibility,
Developed using the pharmacy means of modernization, have the characteristics that it is significant in efficacy, do not generate drug resistance, no drug residue, moreover it is possible to improve
The intestinal environment of chicken improves the immunity of chicken, is a kind of green non-pollution veterinary drug；
The second, the use of Chinese medicine composition of the invention to antibiotic during reduction fowl raising, improves the health status of chicken,
The food safety for improving chicken and its product is of great significance, and economic benefit and social prospect are considerable；
Third, preparation method of the invention, it is intrinsic according to each group in prescription, it is first crushed, is impregnated again, water extraction, second again
The quiet system of alcohol, improves the effective component of the Chinese medicine composition；
Further advantage, target and feature of the invention will be partially reflected by the following instructions, and part will also be by the present invention
Research and practice and be understood by the person skilled in the art.
Specific embodiment
Following example is only to further illustrate the present invention, range that the invention is not limited in any way.
Embodiment 1
Prescription: 30 parts of galla turcica, 15 parts of ginkgo, 18 parts of pueraria lobata, 10 parts of lotus leaf, 7 parts of green tea
(1) galla turcica of recipe quantity, ginkgo, pueraria lobata are crushed, it is spare.
(2) extraction process by water: smashed galla turcica, ginkgo, pueraria lobata, lotus leaf, green tea are impregnated for 24 hours in 37 DEG C of warm water,
Refluxing extraction adds 6 times of water multiple, return time 3h, extraction time 2 times, and filtering is concentrated into medical fluid ratio 1:7, spare.
(3) process for refining: 55% ethyl alcohol being added in (2), 30h is stood after stirring, filters, and recycles ethyl alcohol, is concentrated into thick
Cream, 1.10(40-60 DEG C of density), it is dry, medicinal extract is obtained, crushing sieves with 100 mesh sieve, spare.
(4) proper auxiliary materials (such as lactose, microcrystalline cellulose, one or more combinations in mannitol) will be added in above-mentioned medicinal extract
Granule is made.
Embodiment 2
Prescription: 27 parts of galla turcica, 18 parts of ginkgo, 18 parts of pueraria lobata, 10 parts of lotus leaf, 7 parts of green tea
(1) galla turcica of recipe quantity, ginkgo, pueraria lobata are crushed, it is spare.
(2) extraction process by water: smashed galla turcica, ginkgo, pueraria lobata, lotus leaf, green tea are impregnated for 24 hours in 37 DEG C of warm water,
Refluxing extraction adds 6 times of water multiple, return time 3h, extraction time 2 times, and filtering is concentrated into medical fluid ratio 1:7, spare.
(3) process for refining: 55% ethyl alcohol being added in (2), 30h is stood after stirring, filters, and recycles ethyl alcohol, is concentrated into thick
Cream, 1.10(40-60 DEG C of density), it is dry, medicinal extract is obtained, crushing sieves with 100 mesh sieve, spare.
(4) proper auxiliary materials (such as lactose, microcrystalline cellulose, one or more combinations in mannitol) will be added in above-mentioned medicinal extract
Granule is made.
Embodiment 3
Prescription: 22 parts of galla turcica, 22 parts of ginkgo, 18 parts of pueraria lobata, 10 parts of lotus leaf, 7 parts of green tea
(1) galla turcica of recipe quantity, ginkgo, pueraria lobata are crushed, it is spare.
(2) extraction process by water: smashed galla turcica, ginkgo, pueraria lobata, lotus leaf, green tea are impregnated for 24 hours in 37 DEG C of warm water,
Refluxing extraction adds 6 times of water multiple, return time 3h, extraction time 2 times, and filtering is concentrated into medical fluid ratio 1:7, spare.
(3) process for refining: 55% ethyl alcohol being added in (2), 30h is stood after stirring, filters, and recycles ethyl alcohol, is concentrated into thick
Cream, 1.10(40-60 DEG C of density), it is dry, medicinal extract is obtained, crushing sieves with 100 mesh sieve, spare.
(4) proper auxiliary materials (such as lactose, microcrystalline cellulose, one or more combinations in mannitol) will be added in above-mentioned medicinal extract
Granule is made.
Test example 1
Galla turcica, ginkgo are respectively this prescription monarch drug in a prescription and ministerial drug, and proportions are related to drug effect, therefore use extracorporeal bacteria inhibitor test
Galla turcica and ginkgo proportion are screened.
1. materials and methods
1.1 test strain
C.perfringens type strain ATCC13124
1.2 the preparation of filter paper
The filter paper that water imbibition is strong and homogeneous is selected, breaks into the disk that diameter is 8mm with puncher, is sub-packed in clean dry examination
It is spare after Guan Zhong, 121 DEG C of high pressure sterilization 30min.
The activation of 1.3 bacterial strains
By clostridium perfringens strains, streak inoculation is on TSC plate, and 40 DEG C of Anaerobic culturels are for 24 hours.Picking is typical typical intensive
Bacterium colony is inoculated into 10mLFT fluid nutrient medium, 40 DEG C of Anaerobic culturel 8h.Bacterium solution is diluted to according to 0.5 Maxwell opacity tube
120CFU/mL。
1.4 disk diffusion method
It is drawn in 100 μ L120FU/mL test bacteria liquids to FT nutrient agar with liquid-transfering gun, with spreader even spread 3 times
Then it is smeared one week around plate edge, covers plate, set 3~5min of drying at room temperature.Each plate is placed with small with the tweezers of sterilizing
The heart clamps filter paper, is affixed on media surface, and light paper-pressing sheet, so that it is close to media surface, each scraps of paper center is apart greater than
24mm, scraps of paper anomaly ware outer rim are greater than 15mm.10 μ l products to be tested are drawn respectively to be added drop-wise on filter paper.Plate is inverted, 40 DEG C
The diameter of inhibition zone is observed and measured to Anaerobic culturel for 24 hours, and every group is done 3 repetitions, is averaged.
1.5 grouping
Blank control group: 0.9% sodium chloride solution
Positive controls: penicillin solution
Medicine group: A, B, C, D, E group sterilizes particle, the water dissolution after adding sterilizing.
A group (galla turcica and ginkgo mass ratio 3:1)
B group (galla turcica and ginkgo mass ratio 2:1)
C group (galla turcica and ginkgo mass ratio 1.5:1)
D group (galla turcica and ginkgo mass ratio 1:1)
E group (galla turcica and ginkgo mass ratio 0.5:1)
1.6 inhibition zone criterion: bacteriostasis effect with antibacterial circle diameter be less than 10mm be it is insensitive, 11~15mm it
Between be sensitive, be medium sensitivity between 16~20, it is highly sensitive for being greater than 20mm.
2 disk diffusion method results
Using disk diffusion method detect following galla turcica and ginkgo formula rate to the sensibility of C.perfringens pathogenic bacteria and
Bacteriostasis.As a result 2 be see the table below
| Group | Average antibacterial circle diameter/mm |
| Blank control group | 0 |
| Positive controls | 20.3 |
| A group | 13.2 |
| B group | 23.4 |
| C group | 27.1 |
| D group | 31.9 |
| E group | 15.4 |
It is seen by test result, maximum to C.perfringens antibacterial circle diameter when galla turcica and ginkgo mass ratio 1:1, antibacterial effect
Fruit is most strong.Secondly galla turcica and ginkgo mass ratio 1.5:1, galla turcica and ginkgo mass ratio 2:1.
Test example 2
Fixed galla turcica and ginkgo mass ratio, investigating other components influences C.perfringens fungistatic effect.
Operation is the same as test 1.
| Composition | Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 |
| Galla turcica | 22 parts | 22 parts | 22 parts | 22 parts | 22 parts |
| Ginkgo | 22 parts | 22 parts | 22 parts | 22 parts | 22 parts |
| Pueraria lobata | 0 part | 0 part | 18 parts | 18 parts | 18 parts |
| Lotus leaf | 0 part | 10 parts | 0 part | 10 parts | 10 parts |
| Green tea | 0 part | 7 parts | 7 parts | 0 part | 7 parts |
As a result:
| Group | Average antibacterial circle diameter/mm |
| Blank control group | 0 |
| Positive controls | 20.4 |
| Prescription 1 | 21.7 |
| Prescription 2 | 22.4 |
| Prescription 3 | 25.1 |
| Prescription 4 | 28.6 |
| Prescription 5 | 32.2 |
From the experimental results, 5 inhibition zone of prescription is maximum, strongest bacteriostatic effect；Prescription 5 is compared, 1,2,3,4 fungistatic effect of prescription is poor
It is different more apparent；Prescription 1 is compared, prescription 1 only has two kinds of ingredients of galla turcica and ginkgo, and prescription 2-5 group fungistatic effect is significantly stronger than place
Side 1, illustrates that compatibility effect complements each other between instant component, plays synergistic effect, lacks constituent part and will affect and is certain
Effect.
Test example 3
According to above-mentioned test result, 1,2,3 therapeutic effect of embodiment is further tested using chicken necrotizing enterocolitis chicken model
Card.
(1) enteron aisle lesion score standard
| It comments Point | Enteron aisle disease states |
| 0 point | There is no any lesion； |
| 1 point | Intestinal wall is thinning, frangible, and mucous membrane is without ulcer, but loose fibrin is adhered on surface； |
| 2 points | Mucosa ulcer, the fibrin deposition lesion diameter that the attachment of focal necrosis mucous membrane surface can not closely be wiped are less than 1cm, and lesion quantity is 1 ~ 5； |
| 3 points | Mucosa ulcer, focal necrosis, mucous membrane surface adhere to the fibrin deposition that can not closely wipe, and lesion quantity is 6 ~ 15； |
| 4 points | Mucosa ulcer, focal necrosis, mucous membrane surface adhere to the fibrin deposition that can not closely wipe, and lesion quantity is at 16 or more； |
| 5 points | The length of gangrenosum acne lesion is in 2 ~ 3cm； |
| 6 points | Typical necrosis on a large scale； |
(2) it operates
1. grouping: 3 Day-old Broiler Chickens of the weight ± 5g of 72 health are randomly divided into normal group, A, B, C, D, E6 group, every group 12,
The chicken coop in fumigation is raised respectively.A group is control group, B group is penicillin group, C group is example 1 group, D group is embodiment
2 groups, E group be 3 groups of embodiment；
2. modeling: except for the normal group, other 5 groups of broiler chicken normal diet being fed 20 days, beginning oronasal inoculation produces gas within the 21st day
Capsular clostridium 3 × 108Cfu/ only, in the morning, afternoon and evening each 1 time daily, for three days on end.
3. administration: the 24th day starts, normal group feeds merely normal diet, A group continue to feed merely normal diet, B group hello it is general
Logical feed+injection penicillin (70,000 unit every time is administered for continuous 7 days 2 times a day), C, D, E group feed normal diet+medicine of the present invention
Object (each 15g is administered for continuous 7 days 2 times a day).
4. Testing index
After experiment, scoring small intestine lesion situation, measurement Immune Organs Index (thymus gland, spleen, the bursa of farbricius)
(3) result
1. small intestine lesion situation
1 small intestine lesion score of table
It is minimum by the visible E group scoring of result, illustrate that small intestine lesion is minimum, secondly D group, C group, B group；Compared with the control group, B, C,
D, there were significant differences (P < 0.05) for E group；It is compared with penicillin group, there were significant differences (P < 0.05) for D, E group.Illustrate this hair
Bright prescription proportion is different, and the curative effect of generation can be variant；The embodiment of the present invention 2,3 curative effects are compared with penicillin good effect.
0. immune organ influences situation
Immune Organs Index can reflect the development condition of Immune Organs of Body to a certain extent, and the reduction of Immune Organs Index is said
Bright Development of Immune Organs is inhibited, and immune function reduces.It is on the contrary then good for Development of Immune Organs, immune function enhancing.
By the visible C group Immune Organs Index highest of result, next E group, D group, B group；Compared with the control group, B, C, D, E group
There were significant differences (P < 0.05)；It is compared with penicillin group, there were significant differences (P < 0.05) for D, E group.Illustrate of the present invention group
Side's proportion is different, and the effect of generation can be variant；The embodiment of the present invention 2,3 is known as better immune organ protection compared with mould and makees
With.
Experimental example 2
(1) diseased chicken for collecting 125 chicken necrotizing enterocolitis, has classical symptom, the course of disease is in 3 days.It is randomly divided into 5 groups, every group 25
Only；A group is control group, B group is penicillin group, C group is example 1 group, D group is 2 groups of embodiment, E group is 3 groups of embodiment.
(2) it is administered:
Penicillin group: 70,000 unit every time is administered for continuous 10 days 2 times a day；
Embodiment 1,2,3: each 15g is administered for continuous 10 days 2 times a day.
(3) it evaluates
Invalid: loss of appetite, row's red or even dark brown tarry stool are just；
Improve: appetite makes moderate progress, and red bloody stool disappears；
Cure: normal diet, excrement are in cylindrical type, and there is white lithate on surface.
(4) efficient %=improvement rate+cure rate
As a result as follows:
From the results, it was seen that compared with the control group, there were significant differences (P < 0.05) for B, C, D, E group；With penicillin group pair
Than there were significant differences (P < 0.05) for D, E group.3 groups of effective percentage of embodiment are up to 100%, and cure rate is up to 96%, and prescription ratio is not
Same 1,2 group of cure rate of embodiment is respectively 52%, 76%, and effective percentage is 100%, illustrates present invention treatment highly significant.
Claims (9)
1. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis, which is characterized in that the pharmaceutical composition main component parts by weight
Number is calculated as: 10-50 parts of galla turcica, 5-45 parts of ginkgo, 1-30 parts of pueraria lobata, 1-20 parts of lotus leaf, 1-15 parts of green tea.
2. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 1, which is characterized in that the pharmaceutical composition
The main Composition Weight Parts of object are calculated as: 22-45 parts of galla turcica, 15-35 parts of ginkgo, 15-25 parts of pueraria lobata, 5-18 parts of lotus leaf, green tea
1-10 parts.
3. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 1, which is characterized in that the pharmaceutical composition
The main Composition Weight Parts of object are calculated as: 27-30 parts of galla turcica, 15-22 parts of ginkgo, 15-18 parts of pueraria lobata, 10-15 parts of lotus leaf, green tea
7-10 parts.
4. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 1, which is characterized in that the pharmaceutical composition
The main Composition Weight Parts of object are calculated as: 30 parts of galla turcica, 15 parts of ginkgo, 18 parts of pueraria lobata, 10 parts of lotus leaf, 7 parts of green tea.
5. any one of -4 a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 1, which is characterized in that should
Drug combination preparation is granule, capsule, tablet, pill.
6. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 5, which is characterized in that the pharmaceutical composition
Object preparation is granule.
7. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis according to claim 6, which is characterized in that the pharmaceutical composition
Object preparation granules agent preparation process are as follows:
(1) galla turcica, ginkgo, pueraria lobata are crushed, it is spare；
(2) extraction process by water: smashed galla turcica, ginkgo, pueraria lobata, lotus leaf, green tea are impregnated for 24 hours in 37 DEG C of warm water, reflux
It extracts, adds 5-15 times of water multiple, return time 2-5h, extraction time 1-3 times, filter, be concentrated into medical fluid ratio 1:1-1:10, it is standby
With；
(3) process for refining: being added 40 ~ 80% ethyl alcohol in (2), and 24 ~ 48h is stood after stirring, and filtering is recycled ethyl alcohol, is concentrated into thick
Cream, density 1.10, temperature is 40-60 DEG C, dry, obtains medicinal extract, crushing sieves with 100 mesh sieve, spare；
(4) proper auxiliary materials will be added in above-mentioned medicinal extract and granule is made.
8. according to a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of claim 7, which is characterized in that the pharmaceutical composition system
Auxiliary material described in agent Preparation Technology of Granules is lactose, microcrystalline cellulose, one or more combinations in mannitol.
9. a kind of pharmaceutical composition for treating chicken necrotizing enterocolitis of claim 1-8 any one preparation is in treatment chicken gangrenosum acne
Application in enteritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910834238.7A CN110448621A (en) | 2019-09-05 | 2019-09-05 | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910834238.7A CN110448621A (en) | 2019-09-05 | 2019-09-05 | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110448621A true CN110448621A (en) | 2019-11-15 |
Family
ID=68490754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910834238.7A Pending CN110448621A (en) | 2019-09-05 | 2019-09-05 | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110448621A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451459A (en) * | 2010-10-28 | 2012-05-16 | 陈呈礼 | Chinese medicine for treating fowl plague |
| CN102948641A (en) * | 2012-10-24 | 2013-03-06 | 刘向前 | Natural plant feed additive for poultry |
| CN103550752A (en) * | 2013-11-19 | 2014-02-05 | 青岛农业大学 | Traditional Chinese medicine composition for treating fowl plague |
| CN104873924A (en) * | 2015-04-30 | 2015-09-02 | 新昌县大成生物科技有限公司 | Preparation method of compound micro-ecological preparation effervescent tablets for preventing and treating fowl plague |
-
2019
- 2019-09-05 CN CN201910834238.7A patent/CN110448621A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451459A (en) * | 2010-10-28 | 2012-05-16 | 陈呈礼 | Chinese medicine for treating fowl plague |
| CN102948641A (en) * | 2012-10-24 | 2013-03-06 | 刘向前 | Natural plant feed additive for poultry |
| CN103550752A (en) * | 2013-11-19 | 2014-02-05 | 青岛农业大学 | Traditional Chinese medicine composition for treating fowl plague |
| CN104873924A (en) * | 2015-04-30 | 2015-09-02 | 新昌县大成生物科技有限公司 | Preparation method of compound micro-ecological preparation effervescent tablets for preventing and treating fowl plague |
Non-Patent Citations (4)
| Title |
|---|
| 刘冰等: "鸡坏死性肠炎诊疗与防治策略分析 ", 《吉林畜牧兽医》 * |
| 徐光: "鸡坏死性肠炎的诊疗与防治策略 ", 《吉林畜牧兽医》 * |
| 杨更善: "涩肠止泻散加减治疗鸡坏死性肠炎", 《青海畜牧兽医杂志》 * |
| 陈暄等: "茶叶和红茶菌中有效成分对肠道微生态平衡的作用 ", 《中国茶叶加工》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940155B (en) | Duckling feed for cherry valley duck and preparation method thereof | |
| CN101836691B (en) | Chinese medicinal herb feed additive | |
| CN102805274B (en) | Compound feed for 0-14-day-old wheat type meat duck and preparation method of compound feed | |
| CN105233097A (en) | Veterinary-used traditional Chinese medicine composition for treating piglet diarrhea and preparation method thereof | |
| CN103451032A (en) | Safe and environment-friendly tea seed washing powder and preparation method thereof | |
| CN104855736A (en) | Pig feed and preparation method thereof | |
| CN103815134B (en) | Feed and traditional Chinese medicine composition for treating porcine pathogenic Escherichia coli diseases | |
| CN102671011B (en) | Traditional Chinese medicine compound powder for preventing and treating yellow and white scour of piglets and preparation method thereof | |
| CN115887555B (en) | Traditional Chinese medicine composition for inhibiting aspergillus flavus | |
| CN104886352A (en) | Special healthcare dog food for bitches and preparation method of special healthcare dog food | |
| CN110464791A (en) | A kind of application of yucca spp in prevention chicken necrotizing enterocolitis | |
| CN110404006A (en) | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis | |
| CN110448621A (en) | A kind of pharmaceutical composition for treating chicken necrotizing enterocolitis | |
| CN109646546B (en) | A Chinese medicinal composition for preventing and treating diarrhea of livestock, and its preparation method | |
| CN107308415A (en) | One group is used to treat Chinese medicine composition of cad pig and preparation method thereof | |
| CN107260919A (en) | A kind of composition, preparation method and its application method for being used to prevent and treat swine enteritis | |
| CN103768189B (en) | The Chinese medicine for the treatment of cattle hemorrhagic enteritis | |
| CN108186941B (en) | Composition for promoting growth and fattening of livestock and poultry and preparation method thereof | |
| CN101757069A (en) | Oral medical liquid for treating chicken mixed infection as well as preparation method and application thereof | |
| CN105707898A (en) | Toxin removing and bowel relaxing probiotic composition and preparation method and application thereof | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN101879238A (en) | Medicinal composition for preventing and controlling chicken colibacillosis and preparation method thereof | |
| CN108992559A (en) | For preventing and treating the veterinary Chinese medicinal composition and preparation method thereof of anemopyretic cold and viral influenza | |
| CN104258038A (en) | Traditional Chinese medical composition for treating liver meridian fire exuberance type herpes zoster | |
| CN110354194A (en) | Chinese medicine composition and preparation method thereof for preventing and treating porcine mycoplasmal pneumonia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191115 |